A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of Macitentan at Steady State on the Pharmacokinetics of Riociguat in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Macitentan (Primary) ; Riociguat (Primary)
- Indications Congenital heart defects; Eisenmenger complex; Heart failure; Portal hypertension; Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 07 Feb 2018 Status changed from recruiting to completed.
- 08 Jan 2018 Status changed from not yet recruiting to recruiting.
- 05 Jan 2018 New trial record